1Chekhun, VF, 1Lukianova, NYu., 1Borikun, TV, 1Bezdenezhnykh, NA, 1Shepelenko, IV, 2Bazas, VM, 2Klyusov, AN
1R.Ye. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv
2Kyiv City Clinical Oncological Center
Nauka innov. 2017, 13(5):67-74
https://doi.org/10.15407/scin13.05.067
Section: Research and Engineering Innovative Projects of the National Academy of Sciences of Ukraine
Language: Ukrainian
Abstract: 
The research was aimed at identifying the relationship between the oncogenic (-182, -155) and the onco-suppressive (-122, -200b) microRNAs in tumor cells with clinical and pathological characteristics of breast cancer (BC) and at establishing their clinical significance. MicroRNA levels have been determined by reverse transcription polymerase chain reaction (RT-PCR) in real time. The expression of estrogen (ER) and progesterone (PR) receptors, and Her2/neuepidermal growth factor has been ascertained by immunohistochemical method. The relationship of these microRNAs expression with the disease stage, the presence of metastatic lesions of regional lymph nodes, the differentiation degree, and the tumor molecular subtype has been established. The obtained results have confirmed the involvement of the tested microRNAs in the formation of BC malignancy degree, their association with tumor aggressiveness and have defined the prospects of further studies of the proposed microRNAs panel for their use as BC additional markers.
Keywords: breast cancer, clinical significance, microRNAs
References: 
1. Siegel R. L., Miller K. D., Jemal A. Cancer statistics. California. Cancer Journal for Clinicians. 2016, 66(1): 7-30.
https://doi.org/10.3322/caac.21332
2. Buleten' natcionalnoho kancer-reestru Ukrainu N17 – «Rak v Ukraini", 2014-2015 National Cancer Institute. Kyiv, 2016. 119 p. [in Ukrainian].
3. Chekhun V.F., Sherban S.D., Savtsova Z.D. Heterohenoct' opuholi – dynamichoe sostoyanie. Onkologia (Oncology). 2012, 14(1): 4-12 [in Russian].
4. Pareja F., Marchiò C., Geyer F.C., Weigelt B., Reis-Filho, J.S. Breast Cancer Heterogeneity: Roles in Tumorigenesis and Therapeutic Implications. Current Breast Cancer Reports. 2017, 9(1): 34-44.
https://doi.org/10.1007/s12609-017-0233-z
5. Ellsworth R.E., Blackburn H.L., Shriver C.D., Soon-Shiong P., Ellsworth D.L. Molecular heterogeneity in breast cancer: state of the science and implications for patient care. Seminars in cell & developmental biology. 2017, 64: 65-72.
https://doi.org/10.1016/j.semcdb.2016.08.025
6. Chekhun V.F., Sherban S.D., Savtsova Z.D. Tumor cell heterogeneity. Experimental Oncology. 2013, 35(3): 154-162.
7. Lang J.E., Wecsler J.S., Press M.F., Tripathy D. Molecular markers for breast cancer diagnosis, prognosis and targeted therapy. Journal of Surgical Oncology. 2015, 111(1): 81-90.
https://doi.org/10.1002/jso.23732
8. Chekhun V.F., Borodai N.V., Yurchenko O.V. MikroRNK i opuholevy proces. Onkologia (Oncology). 2012, 15(2): 136-140 [in Russian].
9. Chekhun V.F., Borikun T.V., Lukianova N.Y. Effect of 5-azacytidine on miRNA expression in human breast cancer cells with different sensitivity to cytostatics. Experimental Oncology. 2016, 38 (1): 26-30.
10. O'Bryan S., Dong S., Mathis J.M., Alahari S.K. The roles of oncogenic miRNAs and their therapeutic importance in breast cancer. European Journal of Cancer. 2017, 72: 1-11.
https://doi.org/10.1016/j.ejca.2016.11.004